Bristol-Myers Squibb Company has announced that the company is voluntarily recalling one lot of Eliquis 5 mg tablets to the consumer level. This lot was distributed nationwide in the US to wholesalers ...

Patients with A-fib and only one of the three dose-reduction criteria used in the ARISTOTLE trial—age 80 years or older, body weight 60 kg or less, and creatinine level 1.5 mg/dL or higher—have higher ...

PRINCETON, NJ — One lot of apixaban (Eliquis, Bristol-Myers Squibb) 5-mg tablets is being voluntarily recalled after a consumer complained that a bottle labeled as Eliquis 5 mg actually contained ...

PRINCETON, N.J. & NEW YORK, Jun 27, 2014 (BUSINESS WIRE) -- Bristol-Myers Squibb Company BMY -0.74% and Pfizer Inc. PFE -0.14% today announced that the Committee for Medicinal Products for Human Use ...

Please provide your email address to receive an email when new articles are posted on . Apixaban dose reduction to 2.5 mg twice daily appeared safe after 6 months of full-dose treatment for venous ...

Only anticoagulant proven to show superior risk reductions versus warfarin in three important outcomes: stroke, major bleeding and all-cause death First approval in any market worldwide of ELIQUIS for ...

Bristol-Myers Squibb is recalling a lot of its anticoagulant Eliquis after a customer got a bottle that contained tablets that were half the prescribed dose. The product, however, was manufactured for ...

London, UK - The European Commission has given the green light to two new oral anticoagulants today, for different indications [1,2]. Apixaban (Eliquis, Bristol-Myers Squibb/Pfizer) was approved in ...

Rivaroxaban once daily and dabigatran twice daily showed evidence of lower thromboembolic rates. Apixaban 2.5 mg twice daily was associated with higher rates of ischemic stroke or systemic embolism ...

"Patients with cancer-associated thrombosis are both at risk of recurrent venous thromboembolism and bleeding during extended anticoagulant," said Mahé in a recorded talk of her ASH poster ...

NEW ORLEANS — New data from the AUGUSTUS trial provide insight on the appropriate antithrombotic regimen after ACS or PCI in patients with atrial fibrillation. Perspectives from Arnold Seto, MD, MPA; ...